April 9, 2018 / 1:09 PM / 3 months ago

BRIEF-AbbVie Says Upadacitinib Met All Primary And Ranked Secondary Endpoints In Phase 3 Study In Rheumatoid Arthritis

1 分钟阅读

April 9 (Reuters) - AbbVie Inc:

* UPADACITINIB MEETS ALL PRIMARY AND RANKED SECONDARY ENDPOINTS INCLUDING SUPERIORITY VERSUS ADALIMUMAB IN PHASE 3 STUDY IN RHEUMATOID ARTHRITIS

* ALL RANKED SECONDARY ENDPOINTS ALSO MET IN PHASE 3 STUDY IN RHEUMATOID ARTHRITIS

* PLANS GLOBAL REGULATORY SUBMISSIONS FOR UPADACITINIB IN RHEUMATOID ARTHRITIS IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:

我们的标准：汤森路透“信任原则”

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below